ALK gene rearrangements have been described in 3–5% of lung adenocarcinomas (ADC), and the presence of dysregulated ALK has been described in at least 18 cancer types (reviewed in 1). Since lung cancer is a common type of cancer, an estimated 70,000 cases of non-small cell lung cancer (NSCLC) which have ALK genomic alterations occur… Read article →
Anaplastic lymphoma kinase (ALK) gene rearrangements are found in 3–5% of lung adenocarcinomas (ADC) (2–4, Figure 1), and over 20 ALK fusion partners have been implicated in non-small-cell lung cancer (NSCLC) (5). Thanks to the relatively recent development of small molecule targeted therapies, the ALK oncogene is now targetable using ALK tyrosine kinase inhibitors (TKIs)… Read article →
QIAGEN partners with the Royal Oman Police to establish a national DNA database called Yaqeen.… https://t.co/UnO55tYxqX, QIAGEN reports results for second quarter and first half of 2018: https://t.co/RICyBelEtJ https://t.co/VwVZQuIrFd, QIAGEN partners with U.K. to expand biomarker research in Manchester
Read the full announcement:… https://t.co/tytlFQzoOf, QIAGEN’s QuantiFERON-TB® Gold Plus wins UN migration agency’s tender
Read the full announcement:… https://t.co/WOJPE5YCcc, We're pleased to announce that the artus CMV QS-RGQ MDx Kit (US) is a nominee for Best New Clinical Assay/Kit of 20… https://t.co/lMWFSWako1, 